RIGL News and Press, Rigel Pharmaceuticals Inc.

2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com

2024-06-25 08:35:45 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals ...

Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...

2024-06-17 09:36:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit. However, there are ...

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress PR Newswire - Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML , inc...

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting PR Newswire - Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those...

Rigel to Present at the Jefferies Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , May 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, will presen...

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress PR Newswire Oral presentation of f inal five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA ® (olutasidenib) eff...

2024-05-07 21:46:15 ET Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer...